Biomarkers

A neo-epitope fragment of type I collagen generated by MMP activity, quantifying pathological soft tissue destruction and extracellular matrix turnover.

A matrix metalloproteinase-generated fragment of type III collagen, reflecting extracellular matrix remodeling and enabling assessment of fibrotic activity.

A granzyme B-generated neo-epitope fragment of type IV collagen, enabling non-invasive assessment of T-cell infiltration and basement membrane remodeling in tumor and inflammatory microenvironments.

A neo-epitope fragment of type IV collagen generated by matrix metalloproteinase activity, enabling non-invasive assessment of basement membrane degradation and extracellular matrix remodeling in chronic inflammatory and fibrotic diseases.

A fragment of S100A9 (calprotectin) released by neutrophil elastase measured in blood, enabling precise assessment of active neutrophil-driven inflammation in systemic and tissue-specific conditions.

A cross-linked fragment of type III collagen generated by matrix metalloproteinase activity, enabling non-invasive assessment of fibrolysis and fibrosis resolution.

A neo-epitope fragment of type III collagen released during extracellular matrix remodeling, enabling non-invasive quantification of active fibrogenesis and dynamic assessment of fibrosis progression and treatment response. Manual ELISA kit version: The kit is FOR RESEARCH USE ONLY (RUO) and can only be used in NON-CLINICAL settings. It can not be used IN DIAGNOSTIC PROCEDURES.Hint: […]

A neo-epitope fragment of type III collagen released during extracellular matrix remodeling, enabling non-invasive quantification of active fibrogenesis and dynamic assessment of fibrosis progression and treatment response.

A fragment of C-terminal type VIa3 collagen (Endotrophin), enabling non-invasive quantification of fibrogenesis, tissue remodeling and wound healing across chronic diseases.

A fragment of the C-terminal propeptide of type V fibrillar collagen, enabling non-invasive monitoring of extracellular matrix, myfibroblast and cancer-associated fibroblast (CAFs) formation, indicating fibrotic activity in hepatic and oncological conditions.